Announcements Trials

Browse Landscape

Phase

Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Carcinoma, Intraductal, Noninfiltrating 2 Smoldering Multiple Myeloma 1 Polyps 1 Peripheral Nervous System Diseases 1 Monoclonal Gammopathy of Undetermined Significance 1 Malnutrition 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Dyspareunia 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Breast Neoplasms, Male 1 Breast Carcinoma In Situ 1

Interventions

Carboplatin 195 Cisplatin 117 Paclitaxel 107 Pemetrexed 106 Docetaxel 96 Gemcitabine 89 Radiotherapy 83 Erlotinib Hydrochloride 58 Bevacizumab 55 Etoposide 49 durvalumab 39 pembrolizumab 38 Nivolumab 31 Specimen Handling 30 Magnetic Resonance Spectroscopy 30 Irinotecan 27 Radiosurgery 26 osimertinib 24 Gefitinib 24 Drug Therapy 23 Vinorelbine 22 atezolizumab 20 Topotecan 20 Radiation 16 Cetuximab 16 Taxes 15 Surgical Procedures, Operative 14 Neoadjuvant Therapy 13 Filgrastim 13 Chemotherapy, Adjuvant 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lung Neoplasms × Fatty Acids, Omega-3 × Clear all

NCT03936621 2019-05-07

Omega

British Columbia Cancer Agency

Phase 2 Unknown

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡